This company is engaged in the manufacture,_processing, packaging, and trade of bulk chemicals and other pharmaceutical products for human use. Its business was_incorporated in DATE and was_formed as a_joint_venture invested by the ORGANIZATION ORGANIZATION ORGANIZATION ORGANIZATION ORGANIZATION ORGANIZATION, Limited, and the ORGANIZATION ORGANIZATION ORGANIZATION, Limited, with ORGANIZATION ORGANIZATION of the COUNTRY COUNTRY. The company has a registered_head_office_located in CITY LOCATION_LOCATION_LOCATION COUNTRY COUNTRY COUNTRY. The company is recognised_as NUMBER of the largest pharmaceutical joint_ventures in COUNTRY. The company has_an_SET production_capacity of NUMBER NUMBER units of prescription medicines, vaccines, over-the-counter_(OTC) medicines, and other consumer healthcare products. The company 's_main products_include ORGANIZATION (an anthelmintic), Tagamet (an H2 receptor for gastric ulcers), Contac and ORGANIZATION ORGANIZATION (cold products), PERSON (a non-steroidal anti-inflammatory drug (NSAID)), Seroxat (an anti-depressant), Temaril injection (anti-bacterial), and PERSON (a topical antibiotic), among_others. The company aims_to_grow as a diversified global firm, delivering more products of value and simplifying the operating TITLE.